Adenomas as a risk factor in familial colorectal cancer: implications for screening and surveillance in the UK

This article is protected by copyright. All rights reserved.
Source: Colorectal Disease - Category: Gastroenterology Authors: Tags: Special Article Source Type: research

Related Links:

Source: Biological Rhythm Research - Category: Research Authors: Source Type: research
Publication date: Available online 13 July 2020Source: Pathology - Research and PracticeAuthor(s): Hyun Ji Son, Ha Yoon Mo, Nam Jin Yoo, Sug Hyung Lee
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 13 July 2020Source: Pathology - Research and PracticeAuthor(s): Jamal Halajzadeh, Parisa Maleki Dana, Zatollah Asemi, Mohammad Ali Mansournia, Bahman Yousefi
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 12 July 2020Source: Pathology - Research and PracticeAuthor(s): Milena Vuletic, Snezana Jancic, Sanja Milenkovic, Marinko Paunovic, Biljana Milicic, Nina Jancic, Biljana Perunicic, Zivana Slovic
Source: Pathology Research and Practice - Category: Pathology Source Type: research
BOWEL cancer affects a person's digestive system in a number of ways. Tenesmus is one of the warning symptoms relating to digestion. The condition could signal early bowel cancer. What is tenesmus?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Could this technique help promote wound healing among oncology patients with complex wounds?Wounds
Source: Medscape Today Headlines - Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Date: Friday, 08 28, 2020; Speaker: Luke Gilbert, Ph.D., Assistant Professor, UCSF; Building: Online - Webex, twitter, Facebook Live; URL: ; CME Credit; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
Prostate cancer has been convincingly linked to the sexually transmitted human papillomavirus (HPV) for the first time.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Bowel Cancer | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Gastroenterology | Gastrointestinal Polyps | HNPCC | Lynch Syndrome | Polyps | Study